Volume 3, Issue 4
Editorialp. 319
Genetic biomarkers of placebo response: what could it mean for future trial design?
Author(s): Kathryn T Hall & Ted J Kaptchuk
Editorialp. 315
How will the reporting recommendations for tumor marker prognostic studies affect clinical trials?
Author(s): Sheila E Taube, Daniel F Hayes
News and Viewsp. 319
New hope for bendamustine in the treatment of non-Hodgkin lymphoma
Conference Reportp. 323
Advances in inflammatory bowel diseases 2012
Author(s): Abdo M Saad, Stacy A Kahn, Michele Rubin, David T Rubin
Commentaryp. 329
Autoregressive integrated moving average in clinical trials
Author(s): Ton Cleophas
Special Reportp. 333
Novel oral taxane therapies: recent Phase I results
Author(s): John Paul Flores, M Wasif Saif
Review: Clinical Trail Outcomesp. 343
Etanercept for the treatment of axial spondyloarthritis
Author(s): I-H Song, J Sieper
Review: Clinical Trail Outcomesp. 359
Treatment of heparin-induced thrombocytopenia: what are the contributions of clinical trials?
Author(s): Moonjung Jung, Lawrence Rice
Review: Clinical Trail Outcomesp. 369
The potential role of new targeted therapies in the treatment of advanced non-small-cell lung cancer
Author(s): Francesca Casaluce, Assunta Sgambato, Paolo Maione, Antonio Rossi, Carmine Ferrara, Alba Napolitano, Giovanni Palazzolo, Fortunato Ciardiello, Cesare Gridelli
Review: Clinical Trail Outcomesp. 385
Ixabepilone and eribulin mesylate: two novel agents approved for the chemotherapeutic treatment ofmetastatic breast cancer
Author(s): Yael S Zack, Linda T Vahdat
Review: Clinical Trail Outcomesp. 395
Adjuvanted versus nonadjuvanted influenza vaccines in young children: comparing results from recent clinical trials
Author(s): Leonoor Wijnans, Daniel Weibel, Miriam Sturkenboom
Acknowledgementsp. 412
